eye problems with semaglutide Study reveals potential risk for (Ozempic) users GLP-1 Drugs Could Double Risk

In the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme, which evaluated Wegovy for weight management, the mean increase in heart rate ranged from 2 to 4 beats per minute across different trials , with some individual patients experiencing larger increases

Clinical data across hundreds of participants shows serious adverse events are essentially nonexistent with topical use

Rotate injection sites more aggressively and reduce injection volume per site

10.1016/j.jmb.2017.04.004 75 KreymannB.WilliamsG.GhateiM

This profile has not been claimed by the business owner or representative